In an arthritis model, IL-27 attenuates disease development and histological disease severity (i.e., cell infiltration in the joint, synovial hyperplasia, and joint erosion) by reducing the expansion of Th17 cells and IL-17 levels (63–66), which can reduce nociception (Table 1). This evidence concerns the gene IL17A and arthritic joint disease.